Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease

Documenti analoghi

• Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
  di: Jannis Kountouras, et al.
  Pubblicazione: (2024)
• Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
  di: Chunlong Liu, et al.
  Pubblicazione: (2025)
• Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2026)
• Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Soroor Owrangi, et al.
  Pubblicazione: (2024)
• Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
  di: Sheila L. Noon, et al.
  Pubblicazione: (2025)